|
| |
Halozyme TherapeuticsHalozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine
| Contact Details: |
| |
| |
| |
| |
| |
| Tel: | 858.794.8889 |
| Fax: | |
| Email: | dramsay@halozyme.com |
| WWW: | www.halozyme.com/
|
| |
Recent Publications by Halozyme Therapeutics: |  |
Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
BACKGROUND: This phase 1 study investigated the pharmacokinetics (PK) and... | 18th September, 2009
| Halozyme Therapeutics, Inc., San Diego, California 92121, USA.
| Diabetes Technol Ther. 2009 Jun;11(6):345-52.
DOI Direct Link |
Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial.
Animal-extracted injectable hyaluronidases have been used safely for more... | 8th January, 2008
| Halozyme Therapeutics
| J Infus Nurs. 2007 Sep-Oct;30(5):293-9.
DOI Direct Link |
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
The extracellular matrix is a significant barrier to the effective... | 19th September, 2007
| Halozyme Therapeutics, Inc., 11588 Sorrento Valley Road, San Diego, CA
| Expert Opin Drug Deliv. 2007 Jul;4(4):427-40.
DOI Direct Link |
A recombinant human enzyme for enhanced interstitial transport of therapeutics.
Subcutaneously injected therapeutics must pass through the interstitial... | 20th October, 2006
| Halozyme Therapeutics, San Diego, CA 92121, USA.
| J Control Release. 2006 Aug 28;114(2):230-41. Epub 2006 Jun 7.
DOI Direct Link |
Press Releases on Halozyme Therapeutics:
|
 |
| Halozyme to Present at the BIOCOM Investor Conference on October 26 |
19th October, 2009 |
Halozyme Therapeutics, Inc. |
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today
|
| Halozyme Receives $5.5 Million Payment From Baxter |
6th January, 2009 |
Halozyme Therapeutics, Inc. |
SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the
|
| Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients |
5th January, 2009 |
Halozyme Therapeutics, Inc. |
DEERFIELD, Ill. and SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Baxter
International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today
announced the start of a Phase III clinical trial of
|
| Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target |
8th December, 2008 |
Halozyme Therapeutics, Inc. |
SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
(Nasdaq: HALO), a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix,
|
| Halozyme Therapeutics to Present at Upcoming Investor Conferences |
10th September, 2008 |
Halozyme Therapeutics, Inc. |
SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
(Nasdaq: HALO), a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix,
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 273 times since April 2007, the link to the organisation's website has been followed 48 times This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Halozyme Therapeutics |
